| Literature DB >> 32229460 |
Niki Ver Donck1,2,3, Geert Vander Stichele2,3, Isabelle Huys1.
Abstract
BACKGROUND: Although preference research finds its origins in consumer research, preference elicitation methods have increasingly attracted attention in different decision-making contexts in health care. Simulating real-life decision making is believed to be important during consumer preference elicitation.Entities:
Keywords: consumer research methods; decision making; preference elicitation methods
Year: 2020 PMID: 32229460 PMCID: PMC7157502 DOI: 10.2196/13684
Source DB: PubMed Journal: Interact J Med Res ISSN: 1929-073X
Search strategy.
| Key search terma | Combined with (AND) |
| Preference elicitation | Consumer – Innovative – Scenario based – Simulation – Virtual Reality – Simulation game – Market research – DCE OR conjoint analysis |
| DCEb or CAc | Innovative – Scenario based – Virtual Reality – Simulation game – Market research |
| measuring preferences OR measure preferences OR preference measurement | Consumer – Innovative – Scenario based – Simulation – Virtual Reality – Simulation game – Market research |
aThe key terms were combined using “AND” with each of the individual terms of column 2 in the same row.
bDCE: discrete choice experiment.
cCA: conjoint analysis.
Different steps of a decision process: health care analogy for the different market evolution stages.
| Market evolution stage; Consumer context [ | Health care analogy | |
|
| Individual context | Group context |
| Becoming aware of a need | Receiving a diagnosis | The experiment is described: patients become aware of different alternatives (therapies) |
| Deciding what information to acquire and how to acquire it | Deciding what information (on possible treatments) to acquire and how to acquire it, deciding who (eg, family members, caretakers) needs to be involved in the decision-making process | Deciding what information to use that has been made available |
| Forming decision rules: deciding whether and which options to consider | Forming decision rules: deciding whether and which treatment options to consider | Forming decision rules: deciding whether and which treatment options to consider |
| Deciding whether to choose now, delay, or never choose | Deciding whether to choose a possible treatment, choose no treatment (eg, watchful waiting), choose to delay treatment, or choose not to be involved in the decision process | Deciding whether to choose a possible treatment or choose no treatment (eg, watchful waiting) |
| If choosing now, deciding which option to choose | If choosing now, deciding which treatment option (including the option of watchful waiting) to choose | If choosing now, deciding which treatment option (including the option of watchful waiting) to choose |
Topics of health care guidelines that might benefit from implementing the identified concepts from the consumer research field.
| Guideline and items | Simulating alternatives | Self-reflection | Separated adaptive dual response | Feedback-driven exploration | Arranging profiles in blocks | |
|
|
|
|
|
|
| |
|
| Research question | —b | — | — | xc | — |
|
| Attributes and levels | — | — | — | x | — |
|
| Construction of tasks | — | x | x | x | x |
|
| Experimental design | — | x | x | x | — |
|
| Preference elicitation | — | x | — | x | — |
|
| Instrument design | x | — | — | x | — |
|
| Data collection | x | — | — | x | — |
|
| Statistical analysis | — | — | — | x | x |
|
| Results and conclusions | — | — | — | x | — |
|
| Study presentation | — | — | — | — | — |
| Total ISPOR guideline items that could be improved | 2 | 3 | 2 | 9 | 2 | |
|
|
|
|
|
|
| |
|
| Patient centeredness | — | — | — | — | — |
|
| Representativeness of the sample and generalizability of results | — | — | — | — | — |
|
| Capturing heterogeneity of patients' preferences | — | — | — | — | — |
|
| Established good research practices by recognized professional organizations | — | — | — | — | — |
|
| Effective communication of benefit, harm, risk, and uncertainty | x | — | — | — | — |
|
| Minimal cognitive bias | — | — | x | — | — |
|
| Logical soundness | — | — | — | x | — |
|
| Relevance | — | — | — | x | — |
|
| Robustness of analysis of results | — | — | — | — | — |
|
| Study conduct | — | — | — | — | — |
|
| Comprehension by study participants | x | — | — | — | — |
| Total FDA guideline items that could be improved | 2 | 0 | 1 | 2 | 0 | |
|
|
|
|
| |||
|
| Methodology criteria | x | x | x | x | x |
|
| Sample criteria | x | — | — | — | — |
|
| Analysis criteria | — | — | — |
| x |
|
| Output criteria | — | — | — | x | — |
| Total MDIC guideline items that could be improved | 2 | 1 | 1 | 2 | 2 | |
aISPOR: International Society for Pharmacoeconomics and Outcomes Research.
b—: Guideline topic not impacted by concept implementation.
cx: Guideline topic might benefit from concept implementation.
dFDA: Food and Drug Administration.
eMDIC: Medical Device Innovation Consortium.